Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

Thumbnail for Real-World Impact of Atrial Fibrillation on Cardiovascular Outcomes and Healthcare Resource Utilization in Patients With Chronic Lymphocytic Leukemia

CLL - 169

Real-World Impact of Atrial Fibrillation on Cardiovascular Outcomes and Healthcare Resource Utilization in Patients With Chronic Lymphocytic Leukemia

G Rhys Williams

Poster Presenter: G Rhys Williams

Thumbnail for Real-World Comparison of Bleeding Outcomes Between Acalabrutinib and Zanubrutinib in Anticoagulated CLL Patients: A 6-Month and 1-Year Propensity-Matched Analysis Using the TriNetX Global Network

CLL - 1695

Real-World Comparison of Bleeding Outcomes Between Acalabrutinib and Zanubrutinib in Anticoagulated CLL Patients: A 6-Month and 1-Year Propensity-Matched Analysis Using the TriNetX Global Network

Ansy Patel

Poster Presenter: Ansy Patel

Thumbnail for Efficacy and Safety of Fixed-Duration Venetoclax-Based Therapy in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

CLL - 1709

Efficacy and Safety of Fixed-Duration Venetoclax-Based Therapy in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

anusree haridas

Poster Presenter: anusree haridas

Thumbnail for Global Macroeconomic Burden of Leukemia Attributable to Tobacco: A Value-of-Lost-Welfare Analysis Across 184 Countries

CLL - 1757

Global Macroeconomic Burden of Leukemia Attributable to Tobacco: A Value-of-Lost-Welfare Analysis Across 184 Countries

Kashish Magnani

Poster Presenter: Kashish Magnani

Thumbnail for Real-World Pharmacovigilance Assessment of Hematologic Safety Signals Among Bruton Tyrosine Kinase Inhibitors, Including Pirtobrutinib: Insights From the Food and Drug Administration Adverse Event Reporting System

CLL - 179

Real-World Pharmacovigilance Assessment of Hematologic Safety Signals Among Bruton Tyrosine Kinase Inhibitors, Including Pirtobrutinib: Insights From the Food and Drug Administration Adverse Event Reporting System

Klesta Cocoli

Poster Presenter: Klesta Cocoli

Thumbnail for Characterizing Patient Self-Reported Adherence to BTKis and Symptoms in CLL/SLL Using an Electronic Patient-Reported Outcomes (ePRO) Platform

CLL - 180

Characterizing Patient Self-Reported Adherence to BTKis and Symptoms in CLL/SLL Using an Electronic Patient-Reported Outcomes (ePRO) Platform

Lee Ding

Poster Presenter: Lee Ding

Thumbnail for Cardiovascular Cause-of-Death Trends in Chronic Lymphocytic Leukemia in the BTK Inhibitor Era: A Population-Based Competing Risk Analysis (SEER 2005-2022)

CLL - 183

Cardiovascular Cause-of-Death Trends in Chronic Lymphocytic Leukemia in the BTK Inhibitor Era: A Population-Based Competing Risk Analysis (SEER 2005-2022)

Yasir Aziz

Poster Presenter: Yasir Aziz

Thumbnail for When Symptoms Speak Louder Than Disease: Discordance Between Patient-Reported Symptoms and Objective Progression in Relapsed CLL

CLL - 192

When Symptoms Speak Louder Than Disease: Discordance Between Patient-Reported Symptoms and Objective Progression in Relapsed CLL

Ahmed Elazab

Poster Presenter: Ahmed Elazab

$Thumbnail for Treatment Landscape of Relapsed/Refractory CLL in Low-Resource Countries$

CLL - 239

Treatment Landscape of Relapsed/Refractory CLL in Low-Resource Countries

Muhammad Usman

Poster Presenter: Muhammad Usman

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.